New drug BI 764532 enters first human tests for Tough-to-Treat cancers
NCT ID NCT04429087
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 33 times
Summary
This early-stage study tests a new drug, BI 764532, in adults with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to standard treatments. The drug is designed to help the immune system attack cancer cells. The main goal is to find the highest safe dose and best dosing schedule, with treatment lasting up to 3 years if beneficial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH SMALL CELL LUNG CARCINOMA AND OTHER NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clínica Universidad de Navarra
RECRUITINGPamplona, 31008, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Clinico Universitario De Valencia
RECRUITINGValencia, 46010, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital Universitari Vall D Hebron
RECRUITINGBarcelona, 08035, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital del Mar
RECRUITINGBarcelona, 08003, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
National Cancer Center Hospital East
RECRUITINGChiba, Kashiwa, 277-8577, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Technische Universität Dresden
RECRUITINGDresden, 01307, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Maryland School of Medicine
RECRUITINGBaltimore, Maryland, 21201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pittsburgh Medical Center
COMPLETEDPittsburgh, Pennsylvania, 15232, United States
-
Universitätsklinikum Köln (AöR)
RECRUITINGCologne, 50937, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Universitätsklinikum Würzburg AÖR
RECRUITINGWürzburg, 97078, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63108, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.